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PreviewsTGF-b failed to rescue spontaneous and
death-receptor-mediated T cell apoptosis
in TGF-b-deficient T cells, and enhance-
ment of spontaneous or TCR-induced
death was not observed in T cells defi-
cient in Smad3. One possible explanation
for these results was that TGF-b was
acting intracellularly and exerting its
antiapoptotic effects by maintaining the
integrity of mitochondrial membranes.
Although this study did not examine
apoptosis of Foxp3+ T cells in the thymus,
the results are quite compatible with all of
the observations of Ouyang et al. (2010)
and support the conclusion that the
decreased number of Foxp3+ Treg cells
early in life in the receptor-deficient mice
is secondary to enhanced apoptosis.
Collectively, these studies strongly
support the view that TGF-b is not essen-
tial for the induction of Foxp3 expression
during Treg cell development in the thy-
mus. It is clear in both studies (Liu et al.,
2008; Ouyang et al., 2010) that low
numbers of Foxp3+ thymocytes can be
detected at day 3–4 of life in the TGF-b
receptor-deficient strains. The factors
that are required for the generation of
these cells remain unknown. The studiesfrom the Li laboratory (Ouyang et al.,
2010) demonstrate that the low numbers
of Foxp3+ T cells detected at day 3–4 of
life are secondary to enhanced Bcl-2
family-mediated apoptosis, but the few
surviving cells are highly activated and
proliferating. Why then are relatively nor-
mal numbers of Foxp3+ T cell observed
at 2–4 weeks of age? It is likely that IL-2
is responsible for the expansion of the
Foxp3+ T cells to near normal numbers
on day 14 of life (Liu et al., 2008). In
many respects, the more important take-
home lesson from this series of papers
(Chen et al., 2001; Liu et al., 2008; Li and
Flavell, 2008; Ouyang et al., 2010) is
the equally critical role of TGF-b in the
development of conventional T cells by
enhancing cell survival. Furthermore, it
remains unclear how the TGF-b-mediated
survival signals control and maintain the
balance between the development of
conventional T cells and Treg cells. Lastly,
the cell type(s) responsible for the pro-
duction of TGF-b in the thymus remain
unknown. Although almost all cells can
produce TGF-b, one intriguing possibility
is that thymic Foxp3+ cells themselves
are a major source. It has recently beenImmunityshown (Tran et al., 2009) that activated
Foxp3+ T cells express latent TGF-b
bound to their surface via a leucine-rich
repeat protein termed GARP. Thus, Treg
cells functioning in a positive feedback
loop could provide the TGF-b needed for
their own survival as well as the survival
of conventional T cells.
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In this issue of Immunity, Blanchet et al. (2010) report that human immunodeficiency virus-1 inhibits macro-
autophagy in dendritic cells, attenuating MHC II presentation. Lee et al. (2010) previously revealed the
requirement of autophagic machinery for MHC II presentation of herpes viral antigens.For many years, macroautophagy was
relegated to a role of indiscriminate bulk
degradation during periods of nutrient
stress in eukaryotes. More recent studies,
however, have secured evidence for an
increasing variety of roles for autophagy
during innate and adaptive immune sur-
veillance and pathogen degradation. It
is becoming clear that autophagy has
evolved beyond its origins of ‘‘self-eating’’into well-adapted self-defense (Levine
and Deretic, 2007).
Numerous in vitro studies have shown
that autophagic engulfment of free intra-
cellular bacterial and viral pathogens can
eliminate these pathogens from host
cells. Some pathogens, including Shigella
flexneri and Legionella pneumophila, and
herpes viruses HSV-1 and KSHV, are
able to evade autophagosomal degrada-tion and in some cases even subvert auto-
phagosomes and autolysosomes for their
own proliferation (Levine and Deretic,
2007; Schmid and Munz, 2007). Autoph-
agy also promotes the activation of
proinflammatory responses during innate
immunity, primarily through engulfment
and delivery of pathogen-associated
molecular patterns (PAMPs) to pattern
recognition receptors (PRRs) including32, May 28, 2010 ª2010 Elsevier Inc. 587
Figure 1. Autophagy-Mediated MHC II Presentation of HIV and HSV
Blanchet et al. (2010) demonstrate that HIV-1 is engulfed by autophagosomes after endocytosis (left) in
cultured dendritic cells. These HIV-Gag+ autophagosomes then fuse to lysosomes, in which HIV-related
peptides are processed for presentation toMHC II loading compartments (MIIC). Envelope (Env) protein of
HIV-1 upregulates mTOR signaling to downregulate autophagy, thereby inhibiting presentation to CD4+
T cells and enhancing HIV-1 infection. Lee et al. (2010) show that TLR signaling upon HSV phagocytosis
is required to recruit autophagic machinery (right), including Atg5, Atg7, Beclin-1, PI3K, and LC3, to the
phagosome. Recruitment of this machinery appears to promote phagosome-lysosome fusion, enabling
processing of HSV peptides for presentation to MIICs.
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PreviewsToll-like Receptors (TLRs) (Levine and
Deretic, 2007). Finally, several studies
now show that autophagy can promote
the delivery of cytosolic antigens to the
MHC II loading compartment—aphenom-
enon described as topological inversion
(Deretic, 2009).
A report published recently in Immunity
(Lee et al., 2010), together with another
published herein (Blanchet et al., 2010),
reveal the remarkable convergence of
autophagy-related signaling and machin-
ery with processes of adaptive immune
signaling, primarily through the MHC II
loading compartment. Lee et al. (2010)
exploited cell-lineage-specific Atg5-defi-
cient mice to provide in vivo evidence for
autophagy machinery-dependent den-
dritic cell (DC) antigen presentation to
CD4+ T cells and evidence for Atg5-
dependent presentation of phagocytosed
extracellular antigens. Independently,588 Immunity 32, May 28, 2010 ª2010 ElseviBlanchet et al. (2010) report the identifica-
tion of LC3+ autophagosomal structures
in HIV-1-infected DCs that intercept
and degrade HIV-1, mediating both TLR
signaling and antigen presentation. For
evasion of these ‘‘immunoamphisomes,’’
HIV-1 is shown to specifically inhibit
autophagy in DCs by HIV1-Env-mediated
mTOR activation, thereby dampening
immune signaling and potentiating down-
stream infection of CD4+ T cells.
Atg5/ DCs, though free of any devel-
opmental defect, have reduced CD4+
T cell activation in culture, have dimin-
ished IFN-g production when exposed to
HSV-2, and cause a more rapid onset of
morbidity when mice are exposed to
lethal dosage of virus (Lee et al., 2010).
These phenotypes are suggestive of a
failure to prime T cell responses in the
absence of Atg5. In accordance with pre-
vious in vitro studies (Schmid et al., 2007;er Inc.reviewed in Levine and Deretic, 2007),
these mice were unable to initiate T cell
proliferation in response to the unpro-
cessed cytosolic antigen ovalbumin, con-
firming that autophagy in DCs is required
for proper processing and presentation
of cytosolic antigens on MHC II receptors
(Lee et al., 2010).
Recent evidence indicates that two
core autophagy proteins, LC3 and
beclin-1, are recruited to phagosomes
containing stimulated TLRs in macro-
phages in order to facilitate phagosome-
lysosome fusion and pathogen elimina-
tion (Sanjuan et al., 2007). Lee et al.
(2010) find that MHC II presentation
of phagocytosed antigens was greatly
diminished in Atg5/ DCs, but, impor-
tantly, this signaling reduction only
occurred in the presence of TLR stimula-
tion by LPS. These results support a
model wherein TLR engagement recruits
autophagic machinery to promote deliv-
ery of phagosomal contents to lyso-
somes, in turn providing for antigen pro-
cessing and presentation on MHC II
(Figure 1).
Intriguingly, although the phenomenon
described in Sanjuan et al. (2007) required
Atg5 and Atg12 to recruit LC3 and
beclin-1 to phagosomes, the process
appeared to be distinct from canonical
macroautophagy—shown by complete
absence of characteristic double-mem-
brane structures as visualized by electron
microscopy. Lee et al. (2010) confirmed
that no double-membrane-bound vesi-
cles were present during lysosome-
phagosome fusion events. Interestingly,
although chemical inhibition or targeted
siRNA of autophagy components could
reduce the presentation of phagocytosed
antigen onMHC II receptors, the induction
of canonical macroautophagy by chemi-
cals or starvation could not enhance
MHC II presentation (Lee et al., 2010).
Therefore, although the phagolysosomal
degradation process requires many com-
ponents of autophagosomal machinery
(PI3K, Atg5, Atg7, and Atg12), it is distinct
from metabolic macroautophagy.
What explanation exists for the require-
ment of these autophagy components
for TLR-mediated MHC II presentation?
Although Atg5/ lysosomes appeared
indistinguishable from wild-type lyso-
somes, Lee et al. (2010) are able to show
impairment of proteolysis in Atg5/
phagosomes, correlating with a severely
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fusion. Previous studies have suggested
that the LC3(ATG8) protein can mediate
membrane tethering and hemifusion
(Nakatogawa et al., 2007), and it stands
to reason that the autophagic machinery,
and specifically the delivery of LC3, pro-
motes lysosomal fusion with phago-
somes, thus allowing antigen processing
and ultimately presentation to MHC II.
On the basis of discovery of functions
for autophagy during innate and adaptive
immune responses, Blanchet et al. (2010)
examine what effect, if any, autophagy
might have on HIV-1 infection of DCs.
DCs exhibit rapid immune responses
uponHIV-1 infection, but these responses
are not sufficient to prevent viral propaga-
tion and transmission to CD4+ and CD8+
T cells. Using LC3 as a marker for autoph-
agy, the authors show a dosage-depen-
dent reduction of autophagy in several
classes of DCs upon HIV-1 infection
in vitro. Autophagy activation by rapamy-
cin also failed to induce accumulation of
LC3II in HIV-1 pulsed DCs compared to
unchallenged controls, with accumula-
tion of the autophagy target protein p62
(SQSTM1) confirming a block in autoph-
agy (Blanchet et al., 2010). By all appear-
ances, HIV-1 had shut down autophagy
initiation, and by late time points of infec-
tion the autophagy machinery had been
exhausted.
In the absence of pathogen or nutrient
stress, autophagy is inhibited bymamma-
lian target of rapamycin (mTOR), and this
inhibition must be lifted in order to upre-
gulate autophagy. Blanchet et al. (2010)
monitored downstream targets of mTOR
to reveal a clear increase in mTOR sig-
naling in HIV-1-infected DCs. These data
suggested that HIV-1 was activating the
mTOR pathway in order to block auto-
phagic flux and exhaust available auto-
phagosomes. Importantly, HIV-1DEnv
was unable to activate mTOR activ-
ity, whereas HIV-1 expressing Env but
blocked for viral fusion was sufficient to
upregulate mTOR (Blanchet et al., 2010).
Therefore, HIV-1-encoded Env appears
to trigger the signaling events leading
to upregulation of mTOR independently
of viral fusion, in part through the
CD4 receptor, to downregulate autoph-
agy (Figure 1).
The authors reason that targeted inhibi-
tion of autophagy by HIV-1 might imply
that autophagosomes can interceptHIV-1 and prevent or delay infection, as
was previously reported in macrophage
cells (Kyei et al., 2009). Indeed, confocal
microscopy revealed colocalization of
HIV-Gagwith LC3+ vesicles, which at later
time points fused with lysosomes asmea-
sured by lysosomal marker lamp2 (Blan-
chet et al., 2010). By monitoring these
markers over time, the authors show that
Gag-LC3 colocalization peaks 6–12 hr
after infection, indicating that by this
time point the activity of mTOR has in-
hibited further autophagosome formation
and all available reserves have been
depleted. Electron microscopy confirmed
that HIV-1 was bounded by double-
membrane vesicles during these time
points. To prove that autophagy is inhibit-
ing HIV-1 survival and transfer, Blanchet
et al. (2010) then targeted autophagy
genes LC3 and Atg5 by RNAi. In the
absence of autophagy, HIV-1 showed
increased survival upon endocytosis
and increased transfer to CD4+ T cells.
As one preliminary explanation for this
increased pathogenicity, HIV-1-infected
DCs showed a substantial (50%–60%)
reduction of TNF-a induction by both
TLR4 and TLR8, in line with previous
reports that TLR signaling is boosted
by autophagy under native conditions
(Levine and Deretic, 2007).
Constitutive activation of autophagy in
MHC II-positive cells, including DCs, has
previously been demonstrated (Schmid
et al., 2007). In the tested cells, at least
50% of all autophagosomes were shown
to eventually fuse with MHC II-loading
compartments. Blanchet et al. (2010) con-
firm a marked reduction in MHC II antigen
presentation in autophagy-inhibited DCs,
despite unchanged MHC II cell surface
expression. The authors thus elegantly
show that HIV1-Env-induced signaling is
sufficient to inhibit autophagy, allowing
HIV-1 to escape the native actions of au-
tophagic ‘‘immunoamphisomes’’ to in-
tercept the virus, diminishing the resultant
innate TLR signaling and adaptive antigen
presentation, and ultimately enabling or
increasing CD4-mediated T cell infection
(Figure 1).
The authors of both papers make
specific note of the implications of their
discoveries for antiviral drug develop-
ment. The case for HIV-1 is particularly
striking, given that the authors show that
rapamycin treatment strongly bypasses
Env-induced mTOR activation, inducingImmunityIFN responses in HIV-1-infected DCs
previously only obtained with the cognate
gag peptide itself. These changes were
sufficient to inhibit HIV-1 transmission by
50% in both immature and mature DCs
(Blanchet et al., 2010). Although rapamy-
cin itself is likely to have off-target effects,
more targeted approaches to promote the
upregulation of autophagy in DCs might
be possible.
Although clear evidence is provided
for autophagic mediation of MHC II
presentation, neither group could show
that modulating autophagy could affect
cross-presentation of extracellular anti-
gens to MHC I. In vitro experiments by
Lee et al. (2010) also did not reveal a clear
role for autophagy during MHC I presenta-
tionof an intracellular antigen.However, an
in vitro requirement for autophagy during
class I presentation of intracellular viral
antigens has been reported (English et al.,
2009), and the ultimate delimitation of
autophagy-mediated antigen presentation
remains an open question. It would not be
surprising to find somedegreeof pathogen
and context specificity within DCs, and
these processes remain completely unex-
plored in other antigen-presenting-cell
types such as B cells and epithelial cells.
Targeting and modulating the machin-
ery of autophagy has the potential to
improve both innate immune responses
and MHC-mediated antigen presentation
in response to pathogen infection. As
the universality of these autophagic
presentation mechanisms continues to
be explored, the implications for vaccine
development are likely to become only
more apparent. Continued study of
autophagy and its machinery, in all of its
numerous presentations, will not only
yield a better understanding of an essen-
tial cellular survival mechanism, but also
a dynamic new tool against a grow-
ing number of human and nonhuman
diseases.REFERENCES
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Mechanisms controlling leukocyte adhesion, propulsion and directional migration have not been fully inte-
grated. In this issue of Immunity, Schumann et al. (2010) propose that DCs swarm to T cell zones using
immobilized CCL21 for adhesive random migration and soluble CCL21 for steering.The discovery by Metchnikoff more than
a century ago that phagocytes migrate
by crawling raised fundamental questions
about the adhesive properties of the
crawling surface and how theymight facil-
itate movement. Adhesive migration is
also referred to as haptic movement.
The word ‘‘haptic,’’ from the Greek ‘‘hap-
testhai’’ meaning ‘‘to touch,’’ signifies the
adhesion of a cell to a surface. Two prin-
cipal types of haptic movement can
be distinguished: haptokinesis, where
‘‘kinesis’’ is the Greek word for ‘‘motion
or movement,’’ and haptotaxis, where
‘‘taxis’’ is Greek for ‘‘order.’’ Thus, hapto-
kinesis is movement of a cell along a
surface, but it is generally meant to
convey random movement, as opposed
to haptotaxis, which is meant to convey
ordered or directional movement of a
cell along a surface, where directional
cues are provided by gradients of bound
ligands recognized by receptors on the
migrating cell. In vitro assays have also
been used for identifying migration that
is dependent on soluble chemoattractant
ligands, which may be either chemoki-
netic in nature, if the concentration of che-
moattractant is uniform and movement is
nonvectorial, or chemotactic, if the con-
centration of chemoattractant is nonuni-form and the cell moves in a directional
manner defined by the gradient.
In the early 1990s, efforts to understand
leukocyte transendothelial migration re-
sulted in the multistep model of leukocyte
trafficking, a synthesis of research in the
areas of adhesion and directional migra-
tion (Butcher, 1991; Springer, 1994).
Other models were developed in special-
ized sites such as the lymph node, where
lymphocytes and dendritic cells (DCs)
appear to migrate along tracks defined
by fibroblastic reticular cells (FRCs) and
conduits decorated by chemokines and
adhesion molecules (Germain, 2006;
Baje´noff et al., 2007). Chemoattractants
were initially thought to be presented as
soluble factors, but later evidence for
tethering to surfaces was reported, and
tethering mechanisms were identified,
including genetically encoded transmem-
brane domains and binding to glycosami-
noglycans (GAGs) (Handel et al., 2005).
Still, the precise mechanism of migra-
tion has been difficult to define, and
certain details are not consistent or do
not fit the models at all. In particular,
diverse biophysical states of chemoat-
tractants could be defined, including obli-
gate soluble chemoattractants, obligate
membrane-bound chemoattractants, andchemoattractants that could be either
soluble or membrane bound, converted
through cleavage by specific enzymes.
Importantly, soluble chemoattractants
have been found to induce adhesion-
independent leukocyte migration (La¨m-
mermann et al., 2008).
These complexities are particularly
well-illustrated by the key lymph node
chemokine receptor CCR7 and its ligands
CCL19 and CCL21 (Fo¨rster et al., 1999).
CCR7 is expressed on naive T cells,
central memory T cells, and mature DCs.
CCL21 and, to a much lesser extent,
CCL19 are produced by FRCs. Why two
chemokines exist that bind to the same
homeostatic receptor with similar affinity
has been a mystery. A potential key to
understanding the specific roles of
CCL19 and CCL21 is their striking differ-
ence in structure: CCL21 has an extended
C terminus that mediates GAG binding,
whereas CCL19 lacks this domain and
as such is an obligate soluble chemokine.
With these observations in hand, the field
was poised for a new synthesis for under-
standing leukocyte migration, this time
between kinetic and tactic mechanisms,
as described for the CCR7 system in this
issue of Immunity by Schumann et al.
(2010). This elegant study, based on
